A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Trial Profile

A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of GDC-0199 (ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Venetoclax (Primary) ; Bendamustine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 01 Sep 2016 Planned End Date changed from 1 Sep 2020 to 1 Sep 2018.
    • 01 Sep 2016 Planned primary completion date changed from 1 Sep 2020 to 1 Sep 2018.
    • 01 Feb 2016 Planned End Date changed from 1 Sep 2018 to 1 Sep 2020 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top